arrow
M

Mark A. Schroeder

washington university school of medicine and siteman cancer center
H指数:62
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
2026-08-310
OAAI
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines

急性移植物抗宿主病的临床管理:ASTCT实践指南委员会的循证综述

2026-05-200
OAAI
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

西达基奥仑赛注射液(cilta-cabtagene autoleucel)治疗复发/难治性多发性骨髓瘤的安全性和有效性:一项CIBMTR研究

2026-04-140
OAAI
Multiple Myeloma, Version 5.2026
2026-01-012
PRE
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce GI Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

一项评估Uproleselan抑制E-选择素以减少多发性骨髓瘤自体造血细胞移植期间胃肠道毒性的II期随机、双盲、安慰剂对照试验

2025-11-090
PRE
Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis

新诊断多发性骨髓瘤中lncRNA表达的研究揭示了一个LINC01432-CELF2轴作为凋亡抑制剂

2025-10-060
OA
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

基于克隆型质谱法的血液微小残留病灶检测可预测接受自体造血细胞移植的多发性骨髓瘤患者的预后

2025-05-080
PRE
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025

NCCN Guidelines® Insights: 多发性骨髓瘤,版本 1.2025

2025-05-010
PRE
Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma
2025-01-230
PRE
Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

ASH Research Collaborative关于浆细胞瘤患者COVID-19结局及疫苗影响(COSMIC)的可行性研究与实施:一项针对多发性骨髓瘤患者、用于监测与COVID-19疫苗及感染相关结局的去中心化、真实世界证据研究

BLOOD
IF23.1
2024-11-050
PRE
Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

白血病相关突变(LAMs)在诱导治疗后清除与中危急性髓系白血病的不良预后相关:一项多中心、前瞻性II期试验的 interim 结果

BLOOD
IF23.1
2024-11-050
PRE
Waldenstro m Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024
2024-01-011
OA
Multiple Myeloma, Version 2.2024
2023-12-0123
OA